

## Press Release

5 July 2024

---

### Cessatech announces changes to the Board of Directors



**Cessatech has today appointed Anders Dyhr Dombernowsky-Toft to the Board of Directors at the Company's extraordinary general meeting. The appointment follows significant business progress over the last year. In addition, Peter Birk has resigned as a member of the Board of Directors to focus on other activities.**

Anders comes with long-standing medical and commercial background in senior leadership positions in both large pharma and small biotech. His experience with planning and execution of global launches makes him an important addition to our Board at this pivotal moment for Cessatech.

Following today's appointment, the Board of Directors consists of Martin Olin (Chairman), Charlotte Videbæk, Flemming Steen Jensen, Rachel Curtis Gravesen and Anders Dyhr Dombernowsky-Toft.

"Cessatech is entering a new and exciting period with global commercializing of its lead candidate CT001 for acute pain management, and Anders' broad understanding of the international life sciences sector brings valuable experience to the Board of Directors," said Chairman of the Board of Directors Martin Olin. "I look forward to working with Anders and wish to thank Peter Birk for his valuable contributions to the company during the last years".

#### **For more information about Cessatech, please contact:**

Jes Trygved, CEO

Phone: +45 9387 2309

E-mail: [jes.trygved@cessatech.com](mailto:jes.trygved@cessatech.com)

[www.cessatech.com](http://www.cessatech.com)

#### **About Cessatech A/S**

Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.